- Track your favorite companies
- Receive email alerts for new filings
- Personalized dashboard of news and more
- Access all data and search results
Content analysis
?Positive | ||
Negative | ||
Uncertain | ||
Constraining | ||
Legalese | ||
Litigous | ||
Readability |
H.S. sophomore Avg
|
- 10-K Annual report
- 10.13 Amendment 2012-1 to Senior Management Agreement
- 10.16 Amendment 2012-1 to Amended and Restated Employment Agreement
- 10.18 Amendment 2012-1 to Employment Agreement
- 10.22 First Amendment to Lease
- 21.1 Subsidiaries of the Registrant
- 23.1 Consent of KPMG LLP, Independent Registered Public Accounting Firm
- 31.1 Certification of the CEO Required by Rule 13A-14(A)
- 31.2 Certification of the CFO Required by Rule 13A-14(A)
- 32.1 Certification of the CEO Required by Rule 13A-14(B)
- 32.2 Certification of the CFO Required by Rule 13A-14(B)
- 99.1 Press Release, Dated March 13, 2013
Exhibit 23.1
Consent of Independent Registered Public Accounting Firm
The Board of Directors and Shareholders
Antares Pharma, Inc.:
We consent to the incorporation by reference in the registration statements (Nos. 333-152472, 333-167457 and 333-180832) on Form S-8, registration statements (Nos. 333-61950, 333-96739, 333-103958, 333-133218, 333-142323, 333-144748, 333-158630 and 333-167975) on Form S-3, and registration statements (Nos. 333-114098 and 333-109114) on Form S-2 of Antares Pharma, Inc. of our report dated March 13, 2013 with respect to the consolidated balance sheets of Antares Pharma, Inc. as of December 31, 2012 and 2011, and the related consolidated statements of operations, comprehensive loss, stockholders’ equity, and cash flows for each of the years in the three-year period ended December 31, 2012, and the effectiveness of internal control over financial reporting as of December 31, 2012, which report appears in the December 31, 2012 annual report on Form 10-K of Antares Pharma, Inc.
/s/ KPMG LLP
Minneapolis, Minnesota
March 13, 2013